COMMUNIQUÉS West-GlobeNewswire

Seismic Therapeutic to Participate in Upcoming Investor Conferences
26/10/2026
WATERTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc. today announced that company management will participate in the following investor conferences: Stifel 2026 Healthcare Conference Date: [...]
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
26/10/2026
Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 26, 2026 (GLOBE [...]
Novastra Therapeutics Reports Encouraging First Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at ESMO Congress 2026
26/10/2026
Initial data from an investigator-initiated Phase 1 study provide early proof of concept for systematic immune reprogramming therapy (XIRT™) XIRT is built on Novastra’s proprietary OmniAntigen™ Platform (OAP) designed [...]
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
26/10/2026
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with [...]
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
26/10/2026
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies Dae Gon Ha, Ph.D., [...]
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
26/10/2026
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
26/10/2026
New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across Australia VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: [...]
Affordable Pet Labs Launches Nationwide Validation Study of an At-Home Heartworm Test, and Invites Dog Owners in 52 Cities to Help
26/10/2026
More than 1,500 dogs will receive a complete heartworm test from a visiting APL technician at no cost. If the new method meets the current gold standard, APL plans to bring it to pet parents nationwide, direct to [...]
Amwell® to report third quarter 2026 operating results
26/10/2026
BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL a leading provider of technology-enabled care, will report third quarter 2026 operating results after stock market trading hours on Tuesday, November 3. [...]
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
26/10/2026
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA [...]
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
26/10/2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% [...]
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
26/10/2026
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall [...]
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
26/10/2026
Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD- [...]
InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization
26/10/2026
BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and [...]
Newsweek Places KFSH in Top 4% of World's Smart Hospitals for Digital Maturity and AI
26/10/2026
RIYADH, Saudi Arabia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is one of only 15 hospitals worldwide to receive both the maximum five-ribbon digital maturity rating [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
26/10/2026
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company [...]
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
26/10/2026
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a [...]

Pages